FaceOf: Dr. Faisal Dail, chairman of the Saudi National Committee for Pharmaceutical Industries

FaceOf: Dr. Faisal Dail, chairman of the Saudi National Committee for Pharmaceutical Industries
Dr. Faisal Dail
Updated 29 August 2018

FaceOf: Dr. Faisal Dail, chairman of the Saudi National Committee for Pharmaceutical Industries

FaceOf: Dr. Faisal Dail, chairman of the Saudi National Committee for Pharmaceutical Industries

Dr. Faisal Dail is the chairman of the National Committee for Pharmaceutical Industries (NCPI). NCPI is the leading association for pharmaceutical manufacturers in Saudi Arabia. Dail has been serving in this position since his appointment after election by committee members in March 2018.

His role in the NCPI includes assuring that the NCPI is on the right track to meet its objectives and goals of providing patients with safe, effective and affordable medicine at the best quality.

Dail has almost 20 years of experience in the pharmaceutical industry in Saudi Arabia. He began his career at Merck Sharp & Dohme (MSD) Pharmaceuticals.

Dail has served as the deputy general manager at AJA Pharma Industries Company since May 2014. It is a subsidiary of Saudi Chemical Co., which is a leading joint stock company.

AJA Pharma enjoys many partnerships with global pharma companies in licensing, contract manufacturing and other collaboration forms.

Dail earned his bachelor degree in pharmacy in 1998 from King Saud University in Riyadh, while he obtained his master’s degree from the same university in business administration in 2003.

NCPI, led by Dail, aims to be the moving force in pharmaceutical industry development in the Kingdom to operate the industry along modern lines.

NCPI will participate in the Saudi International Pharmaceutical Exhibition and Conference at the Riyadh International Convention and Exhibition Center as a strategic partner from Nov. 19-21. 

Dail said that the committee’s participation in exhibitions and conferences for the development of pharmaceutical industries in the Kingdom is part of its strategy to increase the production of medicine locally at international quality using national expertise and competencies.

He said that 20 percent of the local market demand for medicines is produced by Saudi pharmaceutical industries. The aim is to increase production to cover 40 percent of local demand by 2020, according to the National Transformation Program (NTP) 2020.